Initiating Basal Insulin Therapy in Patients with Severe Hyperglycemia
Introduction to Basal Insulin Therapy
- The American Diabetes Association recommends initiating basal insulin therapy in patients with severe hyperglycemia (random blood glucose >300 mg/dL) despite being on maximal doses of oral agents 1, 2
- Basal insulin provides relatively uniform coverage throughout the day and night, mainly controlling blood glucose by suppressing hepatic glucose production between meals and during sleep 5, 6
Benefits of Basal Insulin
- Insulin is likely to be more effective than most other agents as third-line (or in this case, fifth-line) therapy, especially when HbA1c is elevated 3, 2
- Long-acting insulin analogs (glargine, detemir) are associated with modestly less overnight hypoglycemia than NPH insulin and possibly slightly less weight gain with detemir 5, 6
Recommended Insulin Regimen
- Initiate long-acting basal insulin (insulin glargine or insulin detemir) once daily in combination with continuing metformin and dapagliflozin 5, 6, 4
- Start with 10 units of basal insulin once daily, typically at bedtime, or use 0.1-0.2 units/kg body weight as the starting dose 5, 6
Insulin Dosing and Titration
- Titrate the basal insulin dose based on fasting glucose targets (typically <130 mg/dL) 5, 4
- Increase by 2-4 units every 3-7 days until fasting glucose targets are achieved 5
Monitoring and Follow-up
- Monitor fasting blood glucose daily during insulin titration 5, 4
- Check HbA1c after 3 months to assess overall glycemic control 1, 4
- Monitor for hypoglycemia, particularly if the patient experiences symptoms or has glucose <70 mg/dL 1, 4